Orexigen Therapeutics, Inc.
NASDAQ: OREX
$0.22
-$0.12 (-34.4%)
Closing price April 3, 2018
Orexigen, Advaxis, Globalstar, and Piedmont Office Realty Trust all posted new 52-week lows Tuesday.
2 years ago
Last Updated: 1 year ago
Anthera Pharmaceuticals, Orexigen Therapuetics, VEON, and New Gold all posted new 52-week lows Monday.
2 years ago
Last Updated: 1 year ago
A few biotech and pharma companies were on the move Wednesday, some making absolutely massive gains on the day, giving more credence to the Trump rally and positive sentiment for the health care...
4 years ago
Last Updated: 1 year ago
The top analyst upgrades, downgrades and initiations seen on Wednesday, March 16, include Chipotle Mexican Grill, Oracle, Orexigen Therapeutics, PulteGroup, Reynolds American and Valeant...
4 years ago
Last Updated: 1 year ago
The top analyst upgrades, downgrades and initiations seen on Monday, February 29, include Huntington Bancshares, Nucor, Orexigen Therapeutics, SanDisk, Square and VIVUS.
4 years ago
Last Updated: 1 year ago
Orexigen Therapeutics has announced receipt of the first of three potential $15 million anniversary milestone payments from Takeda Pharmaceuticals.
5 years ago
Last Updated: 5 years ago
Orexigen Therapeutics shares plunge after termination of cardiovascular outcomes study of the obesity drug Contrave.
5 years ago
The last full week of March was choppy and took away most of the 2015 gains for the Dow and the S&P. Still, investors keep looking for value.
5 years ago
Last Updated: 5 years ago
Source: ThinkstockLooking back at 2014, biotechs had a phenomenal year, and this looks to continue into 2015. The NYSE Arca Biotech index was up over 45% for 2014, and Wells Fargo expects that the...
6 years ago
Last Updated: 9 months ago
Merrill Lynch released an analyst report for Orexigen Therapeutics that sees more than 50% upside for the company.
6 years ago
Last Updated: 6 years ago
A new report from Merrill Lynch highlights five biotechs that have been absolutely crushed but have outstanding potential and catalysts that can drive them much higher.
6 years ago
Many investors believe stocks priced under $10 have much more upside than traditional Dow and S&P 500 stocks.
6 years ago
Last Updated: 6 years ago
Credit Suisse has launched new biotech coverage on Wednesday with two analysts at the firm.
6 years ago
Last Updated: 6 years ago
Source: ThinkstockStocks have pulled back from their all-time highs after escalation of civil war in Iraq, but Friday managed to close higher. Investors remain bullish, and they keep hearing that the...
6 years ago
These are the three analysts stock picks from Wall Street in recent days that were projected to have implied upside of 100% or more.
6 years ago
Last Updated: 6 years ago